שווי כולל של החברה: reshapelifesciences.com (RSLS)

ReShape Lifesciences (RSLS) is developing tools to combat obesity by adapting its surgical profile to the expansion of GLP-1 drugs. This price action shown below, where the Enterprise Value is , links a third-party component assembly model with financial stability. Meanwhile, cash flow relies on equipment sales, while bottom-line profit depends on insurance reimbursement terms.

For ReShape Lifesciences (RSLS), the current EV of reflects the total enterprise value, combining market capitalization with net debt to determine the actual acquisition price. This metric allows for an assessment of the company's fundamental stability, where steady revenue from obesity treatment systems offsets the financial burden during the development of new therapeutic platforms.